Sanofi: Oddo still a buyer

(CercleFinance.com) - Oddo BHF maintains its "outperform" rating on Sanofi shares, along with a target price of 108 euros, after the FDA approved Pfizer's JAK1 inhibitor Cibinqo for the treatment of atopic dermatitis.


Analysts initially saw the drug's safety profile as a barrier to market penetration compared to Sanofi's Dupixent... the specific indication issued by the FDA proves us right, the broker pointed out.

The next few weeks will be focused on the group's clinical business, it continued, expecting three Phase III results in Q1, i.e. the Covid-19 vaccine, the amcenestrant in breast cancer and efanesoctocog alfa in haemophilia A.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.